(RTTNews) - Exelixis, Inc. (EXEL) announced that its supplemental New Drug Application for cabozantinib has been accepted in the U.S. for: the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumors, and the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated extra-pancreatic NET. The FDA assigned a standard review with a Prescription Drug User Fee Act target action date of April 3, 2025.
The company said the sNDA is based on the final results of the phase 3 CABINET pivotal trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated NET: advanced pNET and advanced epNET.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
